Table 1.
Demographic overview of the study population. The numbers are expressed as absolute values (percentage) or median (range).
| Recipients characteristics | |||
|---|---|---|---|
| Gender | Male | 19 | (79%) |
| Female | 5 | (21%) | |
| Age | 58 | (39–70) | |
| Disease | Cirrhosis | 10 | (42%) |
| HCC | 14 | (58%) | |
| LabMELD | 15 | (7–34) | |
| Antiviral therapy | HBV-nucleoside analogues | 24 | (100%) |
| Lamivudine | 13 | (54%) | |
| Tenofovir | 7 | (29%) | |
| Adefovir + Lamivudine | 3 | (13%) | |
| Entecavir | 1 | (4%) | |
| HBV Immunoglobulins (post-LT) | 24 | (100%) | |
| CMV-nucleoside analogues | 5 | (21%) | |
| Valganciclovir | 5 | (100%) | |
| HDV coinfection | 3 | (13%) | |
| Blood transfusion | 23 | (96%) | |
| Pre-LT | AST | 62 | (13–157) |
| ALT | 52 | (14–115) | |
| Hospital stay (days) | ICU | 5 | (1–23) |
| Off ICU | 16 | (7–43) | |
| Ischemic perfusion time (hours) | Cold | 7 | (4–11) |
| Warm | 0.7 | (0.5–1.3) | |
| Donor characteristics | |||
| Gender | Male | 18 | (75%) |
| Female | 6 | (25%) | |
| Age | 52 | (16–57) | |